CD274 and non-small cell lung carcinoma: The CheckMate 9LA clinical trial regimen of nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with only two cycles of platinum doublet-based chemotherapy has shown long-term durable efficacy and a manageable safety profile, leading to the implementation of the regimen in the first-line treatment setting for patients with metastatic NSCLC regardless of PD-L1 status [12].